Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLANASDAQ:GALTNASDAQ:LXEONASDAQ:NKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.93+3.5%$0.99$0.63▼$3.23$32.55M0.37126,357 shs21,985 shsGALTGalectin Therapeutics$3.29+37.7%$1.39$0.73▼$3.30$151.27M0.54388,765 shs5.37 million shsLXEOLexeo Therapeutics$4.24+8.2%$3.28$1.45▼$19.50$130.13M0.52528,088 shs429,734 shsNKTXNkarta$1.82+0.6%$1.87$1.31▼$8.23$128.43M0.721.06 million shs430,106 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma+3.49%-8.95%-5.44%+1.05%+14.70%GALTGalectin Therapeutics+37.66%+149.24%+147.37%+115.03%+41.20%LXEOLexeo Therapeutics+8.16%-5.99%+28.88%+57.62%-72.89%NKTXNkarta+0.55%-9.00%+7.06%+21.33%-65.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma1.8996 of 5 stars3.53.00.00.00.81.70.0GALTGalectin Therapeutics1.4251 of 5 stars3.50.00.00.02.01.70.0LXEOLexeo Therapeutics3.2057 of 5 stars4.52.00.00.01.42.50.6NKTXNkarta3.4298 of 5 stars4.63.00.00.02.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,617.84% UpsideGALTGalectin Therapeutics 3.00Buy$6.0082.37% UpsideLXEOLexeo Therapeutics 3.00Buy$16.60291.51% UpsideNKTXNkarta 3.13Buy$14.33687.55% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, NKTX, GALT, and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/10/2025NKTXNkartaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.005/30/2025LXEOLexeo TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $10.005/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/16/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $15.005/15/2025NKTXNkartaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/15/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.005/13/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $20.004/9/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/8/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $22.004/8/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/ALXEOLexeo Therapeutics$650K216.57N/AN/A$3.53 per share1.20NKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%N/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/11/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.30N/AN/AN/AN/A-85.86%-68.48%8/11/2025 (Estimated)NKTXNkarta-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)Latest ESLA, NKTX, GALT, and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/14/2025Q1 2025NKTXNkarta-$0.44-$0.43+$0.01-$0.43N/AN/A5/12/2025Q1 2025LXEOLexeo Therapeutics-$0.80-$0.99-$0.19-$0.99N/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/26/2025Q4 2024NKTXNkarta-$0.41-$0.35+$0.06-$0.35N/AN/A3/24/2025Q4 2024LXEOLexeo Therapeutics-$0.87-$0.78+$0.09-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.220.22GALTGalectin TherapeuticsN/A0.080.08LXEOLexeo Therapeutics0.013.423.42NKTXNkartaN/A14.4814.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%GALTGalectin Therapeutics11.68%LXEOLexeo Therapeutics60.67%NKTXNkarta80.54%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%GALTGalectin Therapeutics50.10%LXEOLexeo Therapeutics5.30%NKTXNkarta8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableLXEOLexeo Therapeutics5833.20 million31.44 millionNot OptionableNKTXNkarta14070.96 million65.00 millionOptionableESLA, NKTX, GALT, and LXEO HeadlinesRecent News About These CompaniesMizuho Lowers Nkarta (NASDAQ:NKTX) Price Target to $14.00June 12, 2025 | americanbankingnews.comNkarta (NASDAQ:NKTX) Given New $14.00 Price Target at MizuhoJune 10, 2025 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of "Buy" from AnalystsJune 10, 2025 | marketbeat.comBank of America Corp DE Grows Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX)June 8, 2025 | marketbeat.comNkarta CMO David Shook Steps Down, Shawn Rose To SucceedJune 8, 2025 | nasdaq.comNkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune FocusJune 6, 2025 | finanznachrichten.deNkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&DJune 6, 2025 | quiverquant.comNkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune FocusJune 6, 2025 | globenewswire.comMillennium Management LLC Boosts Position in Nkarta, Inc. (NASDAQ:NKTX)June 4, 2025 | marketbeat.comJefferies Financial Group Inc. Boosts Stock Position in Nkarta, Inc. (NASDAQ:NKTX)May 28, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $507,000 in Nkarta, Inc. (NASDAQ:NKTX)May 26, 2025 | marketbeat.comAWM Investment Company Inc. Makes New $996,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)May 23, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Nkarta FY2025 EarningsMay 21, 2025 | marketbeat.comTang Capital Management LLC Acquires 1,643,719 Shares of Nkarta, Inc. (NASDAQ:NKTX)May 20, 2025 | marketbeat.comLeerink Partnrs Analysts Lower Earnings Estimates for NkartaMay 20, 2025 | marketbeat.comWilliam Blair Comments on Nkarta's Q2 Earnings (NASDAQ:NKTX)May 20, 2025 | marketbeat.comNkarta (NKTX) Moves to Buy: Rationale Behind the UpgradeMay 19, 2025 | zacks.comNkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune SpaceMay 15, 2025 | benzinga.comWilliam Blair Downgrades Nkarta (NKTX)May 15, 2025 | msn.comNkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 15, 2025 | finanznachrichten.deNkarta Reports First Quarter 2025 Financial Results and Corporate HighlightsMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesUber Stock Ready to Ride Higher on Waymo PartnershipBy Gabriel Osorio-Mazilli | May 28, 2025View Uber Stock Ready to Ride Higher on Waymo PartnershipTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%Alphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden Driver5 Stocks Set to Soar This SummerBy Ryan Hasson | June 2, 2025View 5 Stocks Set to Soar This SummerTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalESLA, NKTX, GALT, and LXEO Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.93 +0.03 (+3.49%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.96 +0.02 (+2.53%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Galectin Therapeutics NASDAQ:GALT$3.29 +0.90 (+37.66%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.29 0.00 (0.00%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Lexeo Therapeutics NASDAQ:LXEO$4.24 +0.32 (+8.16%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$4.12 -0.13 (-2.95%) As of 06/18/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Nkarta NASDAQ:NKTX$1.82 +0.01 (+0.55%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.83 +0.01 (+0.77%) As of 06/18/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
